|
2019 Conference Publication SWATH-MS profiling identifies prognostic factors for progression- free survival (PFS) In INTEGRATE - A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG)Hayes, Sarah A., Martin, Andrew, Yip, Sonia, Howell, Viive M., Sjoquist, Katrin M., Tsobanis, Eric, Kang, Yoon-Koo, Bang, Yung-Jue, Alcindor, Thierry, O'Callaghan, Christopher J., Tebbutt, Niall C., Simes, John, Goldstein, David and Pavlakis, Nick (2019). SWATH-MS profiling identifies prognostic factors for progression- free survival (PFS) In INTEGRATE - A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG). Annual Meeting of the American-Association-for-Cancer-Research (AACR), Atlanta Ga, Mar 29-Apr 03, 2019. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. doi: 10.1158/1538-7445.AM2019-4531 |
|
2017 Conference Publication Physical Activity for Women with Metastatic Breast Cancer: A Pilot RCTYee, Jasmine, Davis, Glen M., Hackett, Daniel, Beith, Janem M., Wilcken, Nicholas, Currow, David, Emery, Jon, Phillips, Jane, Martin, Andrew, Hui, Rina, Harrison, Michelle, Segelov, Eva and Kilbreath, Sharon L. (2017). Physical Activity for Women with Metastatic Breast Cancer: A Pilot RCT. HOBOKEN: WILEY. |
|
2017 Conference Publication P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS)Wong, Nicole, Nayar, Namrata, Lawrence, Nicola, Stockler, Martin, Martin, Andrew, Yip, Sonia, Yeung, Annie, Friedlander, Michael, Mazhar, Danish, Pashankar, Farzana, Quinn, David, Walker, Roderick, Winstanley, Mark, Weickhardt, Andrew, Hanning, Fritha, Stevanovic, Amanda, Davis, Ian, Toner, Guy and Grimison, Peter (2017). P3BEP (ANZUP 1302): An International Randomised Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours (GCTS). HOBOKEN: WILEY. |
|
2017 Conference Publication The Chest Australia Trial: A Phase II Randomised Controlled Trial of an Intervention to Reduce Time to Consult with Symptoms of Lung CancerEmery, Jon, Murray, Sonya, Campbell, Neil, Walter, Fiiona M., Mazza, Danielle, Habgood, Emily, Kutzer, Yvonne, Martin, Andrew, Goodall, Stephen, Barnes, David and Murchie, Peter (2017). The Chest Australia Trial: A Phase II Randomised Controlled Trial of an Intervention to Reduce Time to Consult with Symptoms of Lung Cancer. HOBOKEN: WILEY. |
|
2017 Conference Publication Predicting Chemotherapy Toxicity in Older Adults: Comparing the Value of the Carg Toxicity Score With Oncologists' Estimates of ToxicityMoth, Erin B., Kiely, Belinda E., Naganathan, Vasikaran, Martin, Andrew, Stefanic, Natalie, Beale, Philip, Grimison, Peter and Blinman, Prunella (2017). Predicting Chemotherapy Toxicity in Older Adults: Comparing the Value of the Carg Toxicity Score With Oncologists' Estimates of Toxicity. HOBOKEN: WILEY. |
|
2017 Conference Publication Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric CancerVasista, Anuradha, Martin, Andrew, Pavlakis, Nick, Sjoquist, Katrin M., Snow, Stephanie, Jonker, Derek, Chua, Yu Jo, Epstein, Richard, Bonaventura, Tony, Khasraw, Mustafa, Varma, Suresh, Singhal, Nimit, Ransom, David, Aubin, Francine, Burkes, Ronald, Lim, Howard, Lemay, Frederic, Begbie, Stephen, Stockler, Martin and Kiely, Belinda (2017). Accuracy and Prognostic Significance of Oncologists' Estimates and Scenarios for Survival Time in A Randomised Phase II Trial of Regorafenib in Advanced Gastric Cancer. HOBOKEN: WILEY. |
|
2017 Conference Publication Can Time to Progression on Last Line Treatment Inform us About Post-Progression Survival Time in Advanced Gastric Cancer?Vasista, Anuradha, Martin, Andrew, Pavlakis, Nick, Sjoquist, Katrin M., Goldstein, David, Shapiro, Jeremy, Karapetis, Chris, Gill, Sanjeev, Jain, Vikram, Liu, Geoffrey, Kannourakis, George, Kim, Yeul Hong, Wigston (Nott), Louise, Snow, Stephanie, Harris, Dean, Jonker, Derek, Chua, Yu Jo, Stockler, Martin and Kiely, Belinda (2017). Can Time to Progression on Last Line Treatment Inform us About Post-Progression Survival Time in Advanced Gastric Cancer?. HOBOKEN: WILEY. |
|
2017 Conference Publication Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma (RCC) in SORCE: an international, placebo-controlled, randomised phase 3 trialLawrence, N. J., Martin, A., Davis, I. D., Troon, S., Sengupta, S., Hovey, E. J., Coskinas, X., Kaplan, R., Ritchie, A. W. S., Meade, A., Eisen, T., Blinman, P. and Stockler, M. R. (2017). Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma (RCC) in SORCE: an international, placebo-controlled, randomised phase 3 trial. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancerVasista, A., Martin, A., Pavlakis, N., Sjoquist, K., Snow, S., Jonker, D., Chua, Y. J., Epstein, R., Bonaventura, A., Khasraw, M., Varma, S. C., Singhal, N., Ransom, D. T., Aubin, F., Burkes, R., Lim, H., Lemay, F., Begbie, S., Stockler, M. R. and Kiely, B. (2017). Accuracy and prognostic significance of oncologists' estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer. 42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid Spain, Sep 08-12, 2017. OXFORD: OXFORD UNIV PRESS. |
|
2017 Conference Publication Predicted Benefits of Adjuvant Sorafenib After Nephrectomy for Renal Cell Carcinoma (RCC) in SORCE: An International, Placebo-Controlled, Randomized Phase 3 TrialLawrence, N., Martin, A., Davis, I. D., Troon, S., Sengupta, S., Hovey, E., Coskinas, X., Kaplan, R., Ritchie, A., Meade, A., Eisen, T., Blinman, P. and Stockler, M. (2017). Predicted Benefits of Adjuvant Sorafenib After Nephrectomy for Renal Cell Carcinoma (RCC) in SORCE: An International, Placebo-Controlled, Randomized Phase 3 Trial. HOBOKEN: WILEY. |
|
2017 Conference Publication USING TRIAL INFRASTRUCTURE EFFICIENTLY: PLATFORM, FACTORIAL, AND UMBRELLA TRIAL DESIGNSMartin, Andrew (2017). USING TRIAL INFRASTRUCTURE EFFICIENTLY: PLATFORM, FACTORIAL, AND UMBRELLA TRIAL DESIGNS. HOBOKEN: WILEY. |
|
2016 Conference Publication Are Multiple Interventions Needed To Influence Physician Prescribing Behaviour: Implications For The Future?Truter, Ilse, Godman, Brian, Baker, Amanj, Bucsics, Anna, Fadare, Joseph, Hesse, Ulrik, Martin, Andrew, Kwon, Hye Young, Zara, Corinne and Bennie, Marion (2016). Are Multiple Interventions Needed To Influence Physician Prescribing Behaviour: Implications For The Future?. HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication LONG-TERM OUTCOMES OF ACCELERATED BEP (BLEOMYCIN, ETOPOSIDE, CISPLATIN) FOR ADVANCED GERM-CELL TUMORS: UPDATED ANALYSIS OF AN AUSTRALIAN MULTICENTER PHASE II TRIALLawrence, Nicola, Martin, Andrew, Toner, Guy, Stockler, Martin, Buizen, Luke, Thomson, Damien, Gebski, Val, Friedlander, Michael, Yeung, Annie, Gurney, Howard, Rosenthal, Mark, Singhal, Nimit, Kichenadasse, Ganessan, Wong, Shirley, Lewis, Craig, Vasey, Paul and Grimison, Peter (2016). LONG-TERM OUTCOMES OF ACCELERATED BEP (BLEOMYCIN, ETOPOSIDE, CISPLATIN) FOR ADVANCED GERM-CELL TUMORS: UPDATED ANALYSIS OF AN AUSTRALIAN MULTICENTER PHASE II TRIAL. HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication A PROSPECTIVE, LONGITUDINAL COHORT STUDY TO INVESTIGATE THE IMPACT OF CHEMOTHERAPY ON COGNITION IN TESTICULAR CANCERStockler, Martin, Whitford, Hayley S., Kalinowski, Pawel, Schembri, Adrian, Toner, Guy, Grimison, Peter, Martin, Andrew, Davis, Ian, Wong, Nicole and Olver, Ian (2016). A PROSPECTIVE, LONGITUDINAL COHORT STUDY TO INVESTIGATE THE IMPACT OF CHEMOTHERAPY ON COGNITION IN TESTICULAR CANCER. HOBOKEN: WILEY-BLACKWELL. |
|
2016 Conference Publication Permanently grafted abrasion resistant nanocomposites for anti-icing applicationsGao, Jing, Martin, Andrew, Yatvin, Jeremy and Locklin, Jason (2016). Permanently grafted abrasion resistant nanocomposites for anti-icing applications. WASHINGTON: AMER CHEMICAL SOC. |
|
2015 Conference Publication RANDOMISED PHASE 3 DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF METHOXYFLURANE WITH PERIPROSTATIC LOCAL ANAESTHESIA TO REDUCE THE DISCOMFORT OF TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY (PAIN-FREE TRUS B): ANZUP 1501Grummet, Jeremy, Davis, Ian, Martin, Andrew, Buchan, Nicholas, Chalasani, Venu, Frydenberg, Mark, Hayne, Dickon, Lalak, Andre, Patel, Manish, Williams, Andrew, Woo, Henry, Lawrence, Nicola, Chan, Howard, Bishop, Claudia, Wong, Nicole, Coskinas, Xanthi and Stockler, Martin (2015). RANDOMISED PHASE 3 DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF METHOXYFLURANE WITH PERIPROSTATIC LOCAL ANAESTHESIA TO REDUCE THE DISCOMFORT OF TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY (PAIN-FREE TRUS B): ANZUP 1501. HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication ANALYSING THE EVIDENCE - THE STATISTICS OF SMALL NUMBERSMartin, Andrew (2015). ANALYSING THE EVIDENCE - THE STATISTICS OF SMALL NUMBERS. HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication RANDOMISED PHASE 3 TRIAL OF THE ADDITION OF MITOMYCIN TO BCG AS ADJUVANT INTRAVESICAL THERAPY FOR HIGH-RISK, NON-MUSCLE-INVASIVE BLADDER CANCER(ANZUP 1301)Chalasani, Venu, Sengupta, Shomik, Stockler, Martin, McCombie, Steve, Hawks, Cynthia, Krieger, Laurence, Anderson, Paul, Grummet, Jeremy, Mitterdorfer, Andrew J., Bishop, Conrad, Beardsley, Emma, Martin, Andrew, Lawrence, Nicola, Wong, Nicole, Chan, Howard, Pysarenko, Mariya, Harper, Matthew, Patel, Manish, Hamid, Akil, Davis, Ian and Hayne, Dickon (2015). RANDOMISED PHASE 3 TRIAL OF THE ADDITION OF MITOMYCIN TO BCG AS ADJUVANT INTRAVESICAL THERAPY FOR HIGH-RISK, NON-MUSCLE-INVASIVE BLADDER CANCER(ANZUP 1301). HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN ANDROGEN DEPRIVATION THERAPY WITH RADIATION THERAPY FOR HIGH RISK, CLINICALLY LOCALISED, PROSTATE CANCER: ENZARAD (ANZUP 1303)Williams, Scott G., Davis, Ian D., Sweeney, Christopher, Stockler, Martin R., Martin, Andrew, Hague, Wendy, Coskinas, Xanthi, Long, Anne, Yip, Sonia, Tu, Emily, Chan, Howard, Lawrence, Nicky, McDermott, Ray, Hughes, Simon, Marchesin, Vittorio, Deignan, Olwyn and Nguyen, Paul L. (2015). RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN ANDROGEN DEPRIVATION THERAPY WITH RADIATION THERAPY FOR HIGH RISK, CLINICALLY LOCALISED, PROSTATE CANCER: ENZARAD (ANZUP 1303). HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN FIRST LINE ANDROGEN DEPRIVATION THERAPY FOR METASTATIC PROSTATE CANCER: THE ANZUP ENZAMET TRIAL (ANZUP 1304)Davis, Ian, Stockler, Martin, Martin, Andrew, Hague, Wendy, Coskinas, Xanthi, Yip, Sonia, Dazo, Carlo, Long, Anne, Lawrence, Nicky, Chan, Howard, McDermott, Ray, Chowdhury, Simon, Marchesin, Vittorio, Deignan, Olwyn, Parulekar, Wendy, Suris, Alexander Montenegro and Sweeney, Christopher (2015). RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN FIRST LINE ANDROGEN DEPRIVATION THERAPY FOR METASTATIC PROSTATE CANCER: THE ANZUP ENZAMET TRIAL (ANZUP 1304). HOBOKEN: WILEY-BLACKWELL. |
